MC4R raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-12 and is reviewed periodically as new material appears.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4R agonist | Subtype most often linked to behavioural effects |
| Other reported targets | MC1R, MC3R, MC5R | Activity is not selective for a single subtype |
| Endogenous ligand class | Melanocortin peptides | Alpha-MSH and ACTH act on the same family |
| Peptide architecture | Cyclic heptapeptide | Lactam bridge between the aspartate and lysine residues |
| Central action | Inferred from animal models | Not directly measured in the human brain |
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
=== Doctor–patient relationship === The relationship is built upon the doctor's obligations of competency, respect for the patient, and appropriate referrals while the patient requirements include decision-making and provides or withdraws consent for any treatment plan. Good communication is key to a strong relationship but has ethical considerations as well, including proper use of electronic communication and clear documentation.
=== Abundance === Deuterium occurs in trace amounts naturally as deuterium gas (2H2 or D2), but most deuterium in the Universe is bonded with 1H to form a gas called hydrogen deuteride (HD or 1H2H). Similarly, natural water contains deuterated molecules, almost all as semiheavy water HDO with only one deuterium. The existence of deuterium on Earth, elsewhere in the Solar System (as confirmed by planetary probes), and in the spectra of stars, is also an important datum in cosmology. Gamma radiation from ordinary nuclear fusion dissociates deuterium into protons and neutrons, and there is no known natural process other than Big Bang nucleosynthesis that might have produced deuterium at anything close to its observed natural abundance. Deuterium is produced by the rare cluster decay, and occasional absorption of naturally occurring neutrons by light hydrogen, but these are trivial sources. There is thought to be little deuterium in the interior of the Sun and other stars, as at these temperatures the nuclear fusion reactions that consume deuterium happen much faster than the proton–proton reaction that creates deuterium. However, deuterium persists in the outer solar atmosphere at roughly the same concentration as in Jupiter, and this has probably been unchanged since the origin of the Solar System. The natural abundance of 2H seems to be a very similar fraction of hydrogen, wherever hydrogen is found, unless there are obvious processes at work that concentrate it.
=== Adverse drug reactions === Ritonavir exhibits hepatic activity. It induces CYP1A2 and inhibits CYP3A4 and CYP2D6. Concomitant therapy of ritonavir with a variety of medications may result in serious and sometimes fatal drug interactions. Due to it being a strong inhibitor (that causes at least a five-fold increase in the plasma AUC values, or more than 80% decrease in clearance) of both cytochrome P450 enzymes CYP2D6 and CYP3A4, ritonavir can severely potentiate and prolong the half-life and/or increase the blood concentration of phenobarbital, primidone, carbamazepine, phenytoin, PDE5 inhibitors like sildenafil, opioids such as hydrocodone, oxycodone, pethidine and fentanyl, antiarrhythmic agents such as amiodarone, propafenone and disopyramide, immunosuppressants such as tacrolimus, voclosporin and sirolimus, neuroleptics like lurasidone and pimozide, as well as some chemotherapeutic agents, benzodiazepines and some ergot derivatives. The FDA has issued a boxed warning for this type of drug interaction. CYP3A4 inducers can counteract the inhibiting effects of ritonavir and lead to drastically reduced levels of "boosted" drugs, increasing the risk of developing drug resistance. Other CYP3A4 inhibitors may have an additive effect with ritonavir, causing increased drug levels.
=== Co-morbidities === BED often happens with diabetes, stroke, and heart disease. People who experience OCD or bipolar disorder have a greater chance of dealing with BED. Additionally, 30 to 40 percent of individuals seeking treatment for weight loss can be diagnosed with binge eating disorder.
=== Genetic labeling === Fluorescence in situ hybridization (FISH), is an example of a genetic labeling technique that utilizes probes that are specific for chromosomal sites along the length of a chromosome, also known as chromosome painting. Multiple fluorescent dyes that each have a distinct excitation and emission wavelength are bound to a probe which is then hybridized to chromosomes. A fluorescence microscope can detect the dyes present and send it to a computer that can reveal the karyotype of a cell. This technique allows abnormalities such as deletions and duplications to be revealed.
Sources: en.wikipedia.org
17 August – SNP MSP John Mason is stripped of the party whip after a Twitter post in which he said that Israel's actions in Gaza did not amount to "genocide", something a party spokesperson describes as "completely unacceptable". 19 August – A rocket being developed by Rocket Factory Augsburg, a German company hoping to launch the UK's first space flight, explodes during a launch test at the Shetland Space Centre. The Scottish Government announces it will hold no further talks with Israeli ambassadors until there is "real progress" in resolving the Gaza conflict. Christina McKelvie, the Scottish Government's Minister for Drugs and Alcohol Policy, announces she will step back from the role while receiving treatment for secondary breast cancer. Her duties will be assumed by fellow ministers Neil Gray and Jenni Minto. 20 August – Data released by National Records of Scotland shows a 12% increase in the number of drug related deaths in Scotland during 2023, with 1,172 deaths that year, an increase of 121 from 2022. Transport Scotland announces that its pilot scheme of subsidising peak-time ScotRail fairs will end in September, having not achieved the goal of encouraging more people to travel by train rather than by road. 21 August – Aberdeen City Council announces that several hundred properties in Aberdeen affected by Reinforced Autoclaved Aerated Concrete are to be demolished and rebuilt at a cost of £150m. 22 August – Edinburgh City Council votes to introduce a tourist tax that it hopes will raise around £50m a year.
In presence of a β-hydrogen, a selenide will give an elimination reaction after oxidation, to leave behind an alkene and a SeO-selenoperoxol. The SeO-selenoperoxol is highly reactive and is not isolated as such. In the elimination reaction, all five participating reaction centers are coplanar and, therefore, the reaction stereochemistry is syn. Oxidizing agents used are hydrogen peroxide, ozone or MCPBA. This reaction type is often used with ketones leading to enones. An example is acetylcyclohexanone elimination with benzeneselenylchloride and sodium hydride.
6 February – Former Chancellor of the Exchequer Kwasi Kwarteng announced he is stepping down from Parliament at the next election. The UK government gives Birmingham City Council to go-ahead to increase its Council Tax by 10% from April. Welsh Government minister Hannah Blythyn announces that the Welsh Government is taking over South Wales Fire and Rescue Service after it was found to have a culture of harassment and misogynism. Elena Whitham resigns from the post of Minister for Drugs and Alcohol Policy for health reasons. Former prime minister Liz Truss launches a campaign to "galvanise" the UK's "secret Conservatives" and fight back against the "left wing extremists" she says have taken over the UK's institutions. 7 February – Sunak faced a call from a Labour MP to apologise after he ridiculed Starmer over his U-turn on "defining a woman" at Prime Minister's Questions. Met Office data obtained by BBC Verify raises questions over UK government suggestions that poor weather conditions had no impact on a fall in English Channel migrant crossings during 2023. The number of crossings were fewer than during the previous year, which the government had said was nothing to do with the weather, but the figures suggest there were fewer days during 2023 when compared to 2022 when migrants could successfully cross the Channel. 8 February – Labour scraps its plans for a £28bn annual green investment, with Sir Keir Starmer saying the policy is unaffordable because of the Conservatives' economic record.
=== Discovery === Enrico Fermi and a team of scientists at the University of Rome reported that they had discovered element 94 in 1934. Fermi called the element hesperium and mentioned it in his Nobel Lecture in 1938. The sample actually contained products of nuclear fission, primarily barium and krypton. Nuclear fission, discovered in Germany in 1938 by Otto Hahn and Fritz Strassmann, was unknown at the time.
This makes frequent, small sublingual or rectal doses a very efficient way to create a stable and constant increase in trough levels. A large amount of estradiol consumed sublingually, and especially orally is converted by the GI tract into estrone and other compounds, causing a higher estrone:estradiol (E1:E2) ratio. This means oral doses are more subject to individual variances in enzymes and physiological chemistry. A high estrone ratio is linked to reduced skeletal growth in pubertal boys and insulin resistance in PCOS. The ratio is also known to be higher in early female puberty (~1:3), and lower in the later stages (~1:5). An average dose intramuscular injection can vary from far above to far below the average female range over the course of a week, depending on an individual's body.
Sources: en.wikipedia.org
Bromley is a large town in Greater London, England, within the London Borough of Bromley. It is 9+1⁄2 miles (15 kilometres) southeast of Charing Cross, and had an estimated population of 97,540 as of 2021. Originally part of Kent, Bromley became a market town, chartered in 1158. Its location on a coaching route and the opening of a railway station in 1858 were key to its development and the shift from an agrarian village to an urban town. As part of the growth of London's conurbation in the 20th century, Bromley Town significantly increased in population and was incorporated as a municipal borough in 1903 and became part of the London Borough of Bromley in 1965. Bromley today forms a major retail and commercial centre. It is identified in the London Plan as one of the 13 metropolitan centres of Greater London.
Vertebrate-wide, the ORs are divided into 13 subclades. The non-Greek-lettered clades are more limited in distribution: A is restricted to the jawless fish; B to the ajwless fish, the Australian ghostshark and the coelacanth; and C to the jawless fish and the ghostshark. The branches labelled "1" and "2" correspond to the two "types" defined by Niimura (2009). Amphioxus have "type 2" ORs. Some groups are less prone to gene duplication than others, suggesting that they may play a non-olfactory role. Tetrapods generally only have the alpha, beta, and gamma subclades, with gamma being the overwhelming majority. An outdated classification of tetrapod (human and frog) ORs included:
Also that year, Schumer wrote a memoir, entitled The Girl with the Lower Back Tattoo. It held the top position on The New York Times Non-Fiction Best Seller list for two weeks in September 2016 and garnered her a nomination for the Grammy Award for Best Spoken Word Album. Schumer made her Broadway debut in 2017 acting in Steve Martin's comedy play Meteor Shower alongside Keegan-Michael Key, Laura Benanti and Jeremy Shamos. The play revolves around two couples in 1993 who spend an evening with each other. David Rooney of The Hollywood Reporter wrote "Schumer is one of four terrific performers who juice the entertainment of this high-sheen production...which would never have made it this far without Martin's name behind it, or more crucially, without the marquee draw of Schumer making her Broadway debut." Schumer was nominated for the Tony Award for Best Actress in a Play losing to Glenda Jackson for the revival of Edward Albee's Three Tall Women. In 2018, she starred in the comedy film I Feel Pretty which received negative reviews from critics. Spotify released the original podcast Amy Schumer Presents: 3 Girls, 1 Keith on June 21, 2018, starring Schumer and her best comedy friends Rachel Feinstein, Bridget Everett and Keith Robinson as they talk about comedy, pop culture, politics and their personal lives. She released her standup special Amy Schumer: Growing (2019) on Netflix to positive reviews. Schumer received a Primetime Emmy Award for Outstanding Writing for a Variety Special nomination.
The lungs are not capable of expanding to breathe on their own, and will only do so when there is an increase in the volume of the thoracic cavity. This is achieved by the muscles of respiration, through the contraction of the diaphragm, and the intercostal muscles which pull the rib cage upwards as shown in the diagram. During breathing out the muscles relax, returning the lungs to their resting position. At this point the lungs contain the functional residual capacity (FRC) of air, which, in the adult human, has a volume of about 2.5–3.0 litres. During heavy breathing as in exertion, a large number of accessory muscles in the neck and abdomen are recruited, that during exhalation pull the ribcage down, decreasing the volume of the thoracic cavity. The FRC is now decreased, but since the lungs cannot be emptied completely there is still about a litre of residual air left. Lung function testing is carried out to evaluate lung volumes and capacities.
Sources: en.wikipedia.org
Bremelanotide binds several melanocortin receptors, and MC4R is the subtype most often cited as responsible for its behavioural effects. Activity at MC1R, MC3R and MC5R is also reported. Selectivity is therefore described as limited rather than precise.
It is not classified as a vasodilator, and its proposed site of action is the central nervous system rather than peripheral vessels. Some trial participants show small transient blood pressure changes. Whether those changes arise centrally or through another route remains an open question.
Most evidence comes from animal models and from indirect human outcomes such as self-reported desire. Direct measurements of receptor occupancy or signalling in the human brain are not available. Published reviews therefore present a plausible pathway rather than a confirmed sequence of events.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.